An expert discusses how the greatest unmet need in minimally invasive benign prostatic hyperplasia (BPH) treatments is achieving durability and retreatment rates that match those of surgical options ...

Muhammed A. Moukhtar Hammad, MBBCh, outlines key findings from a study evaluating testosterone replacement therapy and hearing-related outcomes. Testosterone therapy was not associated with an ...

Krambeck highlights that FANS combine enhanced maneuverability and effective fragment evacuation, leading to higher stone clearance rates and improved procedural outcomes in endourology. In this video ...

Modern visualization tools have reduced fluoroscopy use, enhancing direct visualization in kidney stone procedures. Single-use ureteroscopes offer superior deflection and image quality, though cost ...

VIR-5500 targets PSMA and is being tested in a phase 1 trial for mCRPC, including combination therapy with ARPIs. Interim data showed PSA reductions in all patients and a favorable safety profile, ...

SBRT post-radical prostatectomy showed favorable 4-year BCRFS and manageable safety, offering a faster alternative to conventional radiotherapy. SBRT demonstrated a lower risk of biochemical ...

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...

Aleece Fosnight, MSPAS, PA-C, highlights that although urinary leakage is common, it is not normal—and effective treatment options exist. In this interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, ...

An expert discusses how the current benign prostatic hyperplasia (BPH) treatment landscape is dominated by traditional approaches such as watchful waiting and medical therapy (particularly α-blockers ...

CAN-2409 plus valacyclovir significantly improved disease-free survival compared with placebo plus valacyclovir. Phase 3 data from the PrTK03 trial (NCT01436968) were recently presented at the ...